Hutchison Chi-Med to File for Approval of Two Cancer Drugs in 2016

Hutchison Chi-Med plans to file two New Drug applications for innovative cancer drugs in 2016, said Christian Hogg, CEO of the company, in an upbeat year-end earnings report. The company expects results from a Phase II trial of fruquintinib as a treatment for colorectal cancer soon, which will trigger a milestone payment from Lilly. It also expects milestones from savolitinib, a treatment for kidney and gastric cancer that is out-licensed to AstraZeneca later in 2015. Chi-Med will file for China approval of fruquintinib and US approval of savolitinib. More details.... Stock Symbols: (AIM: HCM) (NYSE: LLY) (NYSE: AZN) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.